Phase 2/3 Trial Fails to Demonstrate Survival Benefit, Leading to Stock Plunge

Compass Therapeutics (CMPX), a U.S.-based biotechnology company, has seen its stock price plummet by approximately 50% after its bispecific antibody, Tovecimig (formerly CTX-009/ABL001), failed to demonstrate a statistically significant improvement in overall survival (OS) in a Phase 2/3 trial (COMPANION-002) for the treatment of biliary tract cancer. In the trial, the Tovecimig and paclitaxel combination therapy showed a median OS of 8.9 months, compared to 9.4 months in the control group, which was not statistically significant. Given that Tovecimig simultaneously blocks DLL4 and VEGF-A, which are involved in cancer cell proliferation, the market reaction has been significant. Investors are concerned that the failure to improve survival may indicate a fundamental lack of efficacy, and this concern has been immediately reflected in the stock price.

Crossover Leading to Statistical Illusion

Compass Therapeutics management attributed the failure of the trial to a high rate of crossover, explaining that this may have distorted the data. In fact, 54% of patients in the control group received Tovecimig after disease progression, which extended their survival to 12.8 months and diluted the significance. However, the median progression-free survival (PFS) in the combination therapy group was 4.7 months, compared to 2.6 months in the control group, which was statistically significant (hazard ratio: 0.44), suggesting some efficacy. In addition, the objective response rate (ORR) was also significantly higher in the combination therapy group (17.1%) compared to the control group (5.3%). Based on this data, the company intends to proceed with a Biologics License Application (BLA) submission to the U.S. Food and Drug Administration (FDA).

Unmet Need in the Biliary Tract Cancer Market

The biliary tract cancer market is estimated at approximately $1 billion, and the 5-year survival rate is less than 10%, representing a significant unmet need. The current standard first-line treatment is AstraZeneca's Imfinzi (durvalumab) in combination with gemcitabine and cisplatin. Tovecimig was developed as a potential follow-up treatment, but its failure to demonstrate OS benefit in the final stage has dampened its prospects. Although it has shown promising results in terms of ORR and PFS, the failure to demonstrate OS, which is the most important clinical benefit evaluated by regulatory agencies, will be a major obstacle to its commercial success.

Limitations in Technology Acquisition and Funding

Tovecimig was originally developed by ABL Bio in South Korea, and Compass acquired global rights (excluding South Korea and China) in 2021 through the acquisition of TRIGR Therapeutics. Compass acquired these rights for approximately $50.3 million in stock and an additional $9 million in milestone payments. As a result, the company's ability to raise capital and continue its pipeline development is now in question, as its key pipeline asset, which it acquired with significant investment, is facing potential failure in the final stage of clinical development. Failure in late-stage clinical trials requires significant additional costs and time for clinical trial design changes or expansion of indications, which can be a significant financial burden for biotechnology companies developing new drugs.